Evidence map›Paper›PMID 10369473›Full record

ArticleBritish journal of pharmacology1999

Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity.

J Galle, U Zabel, U Hübner, A Hatzelmann, B Wagner, C Wanner, H H Schmidt

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 175 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. The Concise Guide to PHARMACOLOGY 2013/14: enzymes.British journal of pharmacology · 2013
    Article
  13. Article
  14. Article
  15. NOX1, 2, 4, 5: counting out oxidative stress.British journal of pharmacology · 2011
    Review
  16. Article
  17. Article
  18. Review
  19. Identification of cytosolic phosphodiesterases in the erythrocyte: a possible role for PDE5.Medical science monitor : international medical journal of experimental and clinical research · 2011
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

J GalleDepartment of Nephrology, Julius-Maximilians-University, Würzburg, Germany.
U Zabel
U Hübner
A Hatzelmann
B Wagner
C Wanner
H H Schmidt
University of Würzburg · DEKlinikum Konstanz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The vasomotor and cyclic GMP-elevating activity of YC-1, a novel NO-independent activator of soluble guanylyl cyclase (sGC), was studied in isolated rabbit aortic rings and compared to that of the NO donor compounds sodium nitroprusside (SNP) and NOC 18. Similarly to SNP and NOC 18, YC-1 (0.3-300 microM) caused a concentration-dependent, endothelium-independent relaxation that was greatly reduced by the sGC inhibitor 1-H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one (ODQ 10 microM; 59% inhibition of dilation induced by 100 microM YC-1) suggesting the activation of sGC as one mechanism of action. Preincubation with YC-1 (3 and 30 microM) significantly increased the maximal dilator responses mediated by endogenous NO in aortic rings that was released upon exposure to acetylcholine, and enhanced the dilator response to the exogenous NO-donors, SNP and NOC 18, by almost two orders of magnitude. Vasoactivity induced by SNP and YC-1 displayed different kinetics as evidenced by a longlasting inhibition by YC-1 (300 microM) on the phenylephrine (PE)-induced contractile response, which was not fully reversible even after extensive washout (150 min) of YC-1, and was accompanied by a long-lasting elevation of intracellular cyclic GMP content. In contrast, SNP (30 microM) had no effect on the vasoconstrictor potency of PE, and increases in intravascular cyclic GMP levels were readily reversed after washout of this NO donor compound. Surprisingly, YC-1 not only activated sGC, but also affected cyclic GMP metabolism, as it inhibited both cyclic GMP break down in aortic extracts and the activity of phosphodiesterase isoforms 1-5 in vitro. In conclusion, YC-1 caused persistent elevation of intravascular cyclic GMP levels in vivo by activating sGC and inhibiting cyclic GMP break down. Thus, YC-1 is a highly effective vasodilator compound with a prolonged duration of action, and mechanisms that are unprecedented for any previously known sGC activator.

Indexed as

AnimalsAorta, ThoracicCyclic GMPEnzyme ActivationEnzyme InhibitorsGuanylate CyclaseIndazolesIn Vitro TechniquesIsoenzymesKineticsMuscle ContractionMuscle RelaxationMuscle, Smooth, VascularMuscle TonusNitric Oxide DonorsNitroprusside1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazoleCyclic GMPEnzyme InhibitorsGuanylate CyclaseIndazolesIsoenzymesNitric Oxide DonorsNitroprussideNitroso CompoundsNOC 18OxadiazolesPhosphoric Diester HydrolasesQuinoxalinesVasodilator Agents

Identifiers

PMID10369473
PMCPMC1565982
OpenAlexW2069881405

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.